Goldman Sachs Group Inc. Purchases 106,041 Shares of OrthoPediatrics Corp. $KIDS

Goldman Sachs Group Inc. grew its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 112.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 200,439 shares of the company’s stock after purchasing an additional 106,041 shares during the period. Goldman Sachs Group Inc. owned about 0.83% of OrthoPediatrics worth $4,937,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. PDT Partners LLC bought a new stake in OrthoPediatrics during the first quarter worth about $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares during the last quarter. GAMMA Investing LLC lifted its stake in OrthoPediatrics by 4,618.2% during the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock worth $261,000 after purchasing an additional 10,391 shares during the last quarter. Deutsche Bank AG lifted its stake in OrthoPediatrics by 57.1% during the fourth quarter. Deutsche Bank AG now owns 14,393 shares of the company’s stock worth $334,000 after purchasing an additional 5,233 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in OrthoPediatrics by 46.8% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,148 shares of the company’s stock worth $348,000 after purchasing an additional 4,508 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of OrthoPediatrics stock in a transaction that occurred on Thursday, August 21st. The shares were bought at an average price of $19.41 per share, for a total transaction of $98,525.16. Following the acquisition, the chief financial officer directly owned 213,065 shares in the company, valued at approximately $4,135,591.65. This trade represents a 2.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 31.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on KIDS shares. Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. JMP Securities set a $35.00 price target on OrthoPediatrics and gave the stock a “market outperform” rating in a research note on Friday, August 8th. Citigroup reiterated a “market outperform” rating on shares of OrthoPediatrics in a report on Friday, August 8th. Finally, BTIG Research decreased their price objective on OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.14.

OrthoPediatrics Stock Up 0.2%

Shares of NASDAQ:KIDS opened at $19.59 on Wednesday. OrthoPediatrics Corp. has a 1 year low of $16.59 and a 1 year high of $32.30. The company has a market cap of $491.12 million, a PE ratio of -10.94 and a beta of 1.06. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The stock’s 50-day moving average is $20.82 and its 200 day moving average is $21.82.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The company had revenue of $61.08 million for the quarter, compared to the consensus estimate of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.